Mineralocorticoid Antagonism and Diabetic Kidney Disease

被引：0
|
作者：
Yuliya Lytvyn
Lucas C. Godoy
Rosalie A. Scholtes
Daniël H. van Raalte
David Z. Cherney
机构：
[1] UHN,Toronto General Hospital Research Institute
[2] University of Toronto,Peter Munk Cardiac Centre
[3] Universidade de Sao Paulo,Instituto do Coracao (InCor), Faculdade de Medicina FMUSP
[4] Amsterdam University Medical Center,Diabetes Center, Department of Internal Medicine
[5] location VU University Medical Center,Department of Medicine, Division of Nephrology, University Health Network
[6] University of Toronto,Department of Physiology
[7] Banting and Best Diabetes Centre,undefined
[8] University of Toronto,undefined
来源：
Current Diabetes Reports | 2019年 / 19卷
关键词：
Mineralocorticoid receptor antagonist; Diabetes; Diabetic kidney disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects
    Barrera-Chimal, Jonatan
    Lima-Posada, Ixchel
    Bakris, George L.
    Jaisser, Frederic
    [J]. NATURE REVIEWS NEPHROLOGY, 2022, 18 (01) : 56 - 70
  • [22] Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease
    Lerma, Edgar
    White, William B.
    Bakris, George
    [J]. POSTGRADUATE MEDICINE, 2023, 135 (03) : 224 - 233
  • [23] Renoprotective Effects of Mineralocorticoid Receptor Antagonists Against Diabetic Kidney Disease
    Bayne, Sarah
    Lefevre, James
    Olstinske, Kayla
    Ravindran, Sreenithya
    Munusamy, Shankar
    [J]. ADVANCED BIOLOGY, 2024, 8 (03):
  • [24] Mineralocorticoid Receptor Pathway and Its Antagonism in a Model of Diabetic Retinopathy
    Zhao, Min
    Gelize, Emmanuelle
    Levy, Rinath
    Moulin, Alexandre
    Azan, Frederic
    Berdugo, Marianne
    Naud, Marie-Christine
    Guegan, Justine
    Delaunay, Kimberley
    Pussard, Eric
    Lassiaz, Patricia
    Bravo-Osuna, Irene
    Herrero-Vanrell, Rocio
    Behar-Cohen, Francine
    [J]. DIABETES, 2021, 70 (11) : 2668 - 2682
  • [25] Mineralocorticoid Receptor Antagonism Improved the Metabolic Function in a Mouse Model With Chronic Kidney Disease and Obesity
    Ramirez, Roberto Palacios
    Bonnard, Benjamin
    Jaisser, Frederic
    [J]. HYPERTENSION, 2019, 74
  • [26] Characterizing the cellular and molecular landscape of mineralocorticoid action and antagonism in the kidney
    Miguel, Veronica
    Drueke, Tilman B.
    [J]. KIDNEY INTERNATIONAL, 2024, 105 (06)
  • [27] Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease
    Verma, Ashish
    Patel, Ankit B.
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2021, 32 (05): : 261 - 263
  • [28] Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease
    Al Dhaybi, Omar
    Bakris, George L.
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 : 69 - 76
  • [29] The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: Progress and challenges
    Yang, Pingping
    Huang, Tianlun
    Xu, Gaosi
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2016, 65 (09): : 1342 - 1349
  • [30] Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease
    Wu, Yichuan
    Lin, Huanjia
    Tao, Yuan
    Xu, Ying
    Chen, Jiaqi
    Jia, Yijie
    Zheng, Zongji
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
12345